Retrospective analysis of 303 patients who underwent allogeneic hematopoietic stem cell transplantation identified 35 (11.5%) with adenovirus infection. Among them, 22 received specific therapy. As first-line therapy, 18 were treated with intravenous ribavirin, 3 with cidofovir, and 1 with vidarabine. Moreover, 2 received donor leukocyte infusion in combination with ribavirin, and 1 received it after failing to respond to other therapies. Seven survived (31.8%; 3 of 13 who received ribavirin alone and 2 of 3 who received cidofovir). Among the 5 patients treated with combined strategies, 2 who received donor leukocyte infusions showed clearance of all symptoms. Acute graft-versus-host disease grade у3 ( ) and a long delay between infection and P p .01 treatment ( ) correlated with a greater risk of treatment failure. In conclusion, ribavirin and vidarabine P p .05 are ineffective options, particularly for patients at who are high risk of acquiring disseminated adenovirus disease. Conversely, cidofovir or donor leukocyte infusions seem to be encouraging approaches if initiated early.
The incidence of invasive adenovirus infections has been reported in as many as one-fifth of hematopoietic stem cell transplantation (HSCT) recipients over the past few years [1] [2] [3] [4] [5] [6] [7] . This probably is attributable to the increasing number of patients, particularly children, receiving unrelated or related HLA-mismatched T celldepleted grafts [1, 4, 7] .
No specific antiviral therapy of proven value currently exists for severe adenovirus infection in immunocompromised hosts, particularly in patients undergoing HSCT. Different antiviral regimens are used when adenovirus infection is suspected or diagnosed. They include intravenous immunoglobulins (IVIGs) alone [4] or in combination with ribavirin [1, 8, 9] , ganciclovir, or vidarabine [10, 11] , with anecdotal case reports of resolution of localized adenovirus disease in uncontrolled studies [12] . The outcome remains poor for patients with disseminated or invasive disease [1] . The recently reported successful treatment of adenovirus disease with cidofovir [13] or with donor leukocyte infusion (DLI) [14] is worth further consideration.
Here, we retrospectively describe our experience of treatment of adenovirus infection among 22 consecutive recipients (pediatric and adult patients) of allogeneic HSCT in our unit from May 1985 through November 1999.
PATIENTS AND METHODS

Patient characteristics.
Adenovirus was isolated from 35 of 303 consecutive allogeneic HSCT recipients, with an overall incidence rate of 11.5% (table 1) . Among those patients who developed adenovirus infection, 22 received specific therapy and 13 did not. As shown in table 2, most patients who were treated were NOTE. Data are percentage of patients, unless otherwise indicated. Disease, probable or definite disease; infection, asymptomatic infection; mortality, adenovirus-related mortality; overall mortality, mortality among patients with adenovirus infection; MUD, matched unrelated donor.
a Or mismatched family member.
children with hematologic malignancies. Most received unrelated ( ) or related partially HLA-matched grafts n p 16 ( ). Eleven of these 22 patients underwent T cell-depleted n p 3 bone marrow transplantation (BMT), and 86% received antithymocyte globulins either before the graft as prophylaxis for graft-versus-host disease (GVHD) and/or after the graft as GVHD treatment. Finally, 13 (59%) patients developed acute grade 2-4 GVHD.
The characteristics of the 13 untreated patients are summarized in table 2. Notably, in this group, more patients received matched sibling bone marrow ( ) and methotrexate n p 9 combined with cyclosporin as GVHD prophylaxis. Moreover, fewer patients received antithymocyte globulins and none developed acute grade 3-4 GVHD.
Adenovirus detection and serotyping. Surveillance with use of the IDEIA test (Dako) and cultures of throat, nasopharynx, urine, stool, and conjunctiva were done twice weekly for most inpatients and weekly or every 2 weeks for most outpatients throughout the first 100 days after HSCT. Other samples (bronchoalveolar lavage fluid, blood, and CSF) were cultured as clinically indicated. Biopsy specimens were processed for routine histological studies; adenovirus was identified by characteristic histological changes and immunohistologically with fluorescent antibody staining. Moreover, adenovirus was sought in biopsy specimens by means of conventional culture on human diploid fibroblast cells and PCR assay. Adenovirus serotyping was done for 21 patients [15] . Serotypes 1 ( ), n p 6 2 ( ), and A31 ( ) were most commonly identified. n p 7 n p 4 Other serotypes detected were serotype 8 ( ), serotype 5 n p 1 ( ), and serotype 3 ( ). Antibody activity of patients' n p 1 n p 2 and donors' serum against adenovirus antigens was not measured before transplantation.
Definition of adenovirus infection. Adenovirus infection was defined according to the adapted Wisconsin criterita [4] . Definite disease was defined by either the presence of adenovirus nuclear inclusions, by a positive result of tissue culture or PCR assay from a sterile site (excluding the gastrointestinal tract), or by a positive immunohistological study with compatible symptoms without other identifiable cause. The remaining 7 patients had adenovirus isolated at a single site (stool, 6; urine, 1) without compatible clinical symptoms. Adenovirus first was identified at a median of 44 days after HSCT (range, 5 days before to 184 days after). The median duration of positive culture results before treatment was 21 days (range, 11-40 days). Adenovirus was isolated at diagnosis of infection from a mean of 1.6 sites (range, 1-3 sites).
Among the untreated group ( ), the time between n p 13 HSCT and the first isolation of adenovirus was 13-120 days after transplantation (median, 46 days). Overall, it was most commonly isolated from 1 site per patient. The median duration of positive culture results for the 11 patients whose adenovirus cleared spontaneously was 25 days (range, 10-60 days). Two patients had probable disease (colitis, 1; hemorrhagic cystitis, 1). The 11 other patients had adenovirus isolated from stool and were asymptomatic.
Treatment of adenovirus infections. Table 4 shows treatments that patients received for adenovirus infections. Eighteen patients (patients 1-18) received ribavirin as part of first-line therapy, 13 alone and 5 in association with other treatments (cidofovir, 1; vidarabine, 2; and DLI, 2). Among these patients, 2 (patients 8 and 12) were given 2 successive courses of ribavirin. Seven patients (patients 6, 7, 9, 12, 14, 16, and 18) received a second-line treatment after failure of this first-line therapy (vidarabine, 2; vidarabine plus cidofovir, 1; cidofovir, 2; vidarabine plus second course of ribavirin, 1; and DLI plus second course of ribavirin, 1). Finally, 1 patient (patient 9) received a third-line treatment (DLI) after failure of treatment with ribavirin, vidarabine, and cidofovir. Three of these 18 patients treated with ribavirin were treated for definite disease, 10 for probable disease, and 5 for asymptomatic adenovirus infection.
Three patients received cidofovir only as part of first-line therapy (patients 21-23). Two had asymptomatic infection, and 1 received prophylactic cidofovir (patient 22). This latter patient underwent a familial haplo-identical HSCT for hemophagocytic Ribavirin was given iv at a loading dosage of 35 mg/kg followed by 25 mg/kg every 8 h for a total of 10 days. Cidofovir with concomitant probenecid was given iv at a dosage of 5 mg/ kg each week for 2 weeks and then every 2 weeks for a total of 4 doses. Patient 22 received prophylactic cidofovir (5 mg/ kg every 2 weeks) for 10 weeks (between day 60 and day 240 after HSCT). Vidarabine was given iv at a dosage of 10 mg/kg per day for 5 days in a 2-3-h infusion as 1 course. Statistical analysis. Means were compared by the Student's t test or by the Mann-Whitney U test. Univariate analysis of risk factors associated with failure of antiviral therapy was done by use of the x 2 and Fisher's exact tests. Factors reviewed included age of the patient, time between adenovirus infection and treatment, time of first positive culture result, staging of adenovirus infection, number of sites of infection, presence of acute GVHD, stem cell donor source, T lymphocyte depletion of the bone marrow, and administration of antithymocyte globulins.
RESULTS
Treated group.
Thirteen patients received iv ribavirin as the only first-line treatment. All completed the full 10 days (table 4) . Among them, 5 had asymptomatic adenovirus infection, 5 had probable disease, and 3 had definite disease. Two of the 5 with asymptomatic adenovirus infection (patients 1 and 4) recovered, and 3 (patients 5, 12, and 16) died, despite 2 receiving second-line therapy (1 each cidofovir and vidarabine). The treatment was successful initially for patient 16, but the infection eventually relapsed, and he died from adenovirus disease and acute GVHD. Two of the 5 patients with probable disease (patients 10 and 14) recovered, but patient 14 relapsed with adenovirus disease 167 days later. Ribavirin combined with vidarabine was readministered unsuccessfully. The other 3 patients with probable disease died, 2 from adenovirus disease (patients 9 [despite successive treatments including vidarabine, cidofovir, and DLI] and 13), and 1 (patient 11) from cytomegalovirus (CMV)-associated pneumonitis. All 3 patients with definite disease (patients 2, 3, and 7) died from adenovirus infection. In conclusion, only 3 of 13 patients who received ribavirin as the only first-line therapy survived, and 10 died from disseminated adenovirus disease, associated with acute GVHD (in 6 patients), graft failure (in 1 patient), or CMVassociated pneumonitis (1 patient).
Five patients, all with probable disease, received ribavirin in association with other treatments (patients 6, 8, 15, 17, and 18) . Two survived, 1 of them (patient 6) was treated with ribavirin, DLI, and cidofovir, and the other (patient 8) was treated with the combination of ribavirin and cidofovir.
Of 3 patients given cidofovir as first-line therapy, 2 survived (patients 21 and 23). Both had asymptomatic adenovirus infection. One died (patient 22) from adenovirus disease, despite ). Two of them died from disseminated n p 2 adenovirus infection (1 each asymptomatic and probable disease), and 11 recovered with a median spontaneous clearance of virus excretion of 25 days (range, 10-60 days). Four other patients died from causes unrelated to adenovirus infection.
The 2 patient groups (treated or untreated) were not comparable. Indeed, the former included more patients with highrisk factors. There was a substantially higher proportion of children with high-grade adenovirus disease, recipients of unrelated or HLA-mismatched grafts, and patients receiving T cell-depleted bone marrow in combination with antithymocyte globulins.
Risk factors for treatment failure. There were significant differences in the probability of failure of antiviral therapy in relation to 2 factors: acute GVHD grade у3 ( ) and long P p .01 delay between adenovirus infection and treatment ( ). P p .05
DISCUSSION
Adenovirus infections are emerging as an important cause of morbidity and mortality after allogeneic HSCT [1] [2] [3] [4] [5] [6] [7] . Indeed, 2%-21% of patients have been reported to develop significant adenovirus infection, resulting in an adenovirus-related mortality rate of 10%-60%, depending essentially on the level of the posttransplantation immunodeficiency. It was thought that the source of infection in most cases was endogenous virus reactivation as a result of posttransplant immunosuppression.
Recently, as many as 65% of child recipients of unrelated HSCT have positive culture results for adenovirus at some time during their hospitalization [4] . The highest mortality rate, approaching 60%, occurs among recipients with invasive and/or disseminated disease [2] . Significant risk factors for developing invasive adenovirus disease are the presence of moderate to severe acute GVHD, use of steroids and other immunosuppressive agents, isolation of adenovirus from у2 sites, HLA-mismatched or unrelated transplants, and use of T cell-depleted bone marrow [1] [2] [3] [4] [5] [6] [7] . Moreover, pediatric patients appear to be infected by adenovirus more frequently and earlier than their adult counterparts [1, 4, 7] .
Our data are comparable to those of other reports, with an overall incidence of 11.5% and a mortality rate of 41% (table 1). Our incidence of adenovirus disease (6.8%) is exactly the same as that in the Wisconsin study [4] , with a comparable group of patients. Indeed, both of these studies included a large number of children who received T cell-depleted grafts from a matched unrelated donor or a mismatched family member. In addition, in our series, most of this high-risk population received pre-and/or posttransplant antithymocyte globulins.
Treatment of established adenovirus disease was disappointing. Various methods have been tried, such as high-dose IVIGs, ribavirin, or vidarabine [1, 4, 8-12, 16, 17] . However, the clinical efficacy of these agents remains unclear. Of the 50 reported patients who received ribavirin as first-line therapy, only 15 (30%) had clearance of adenovirus infection, mostly those with adenovirus-associated hemorrhagic cystitis (8 of 17) [12, [18] [19] [20] [21] [22] [23] . High bladder concentrations could explain why ribavirin may have been effective for such patients. Our data are similar; indeed, only 4 (30.8%) of 13 patients who received ribavirin as the only first-line treatment recovered. One of them experienced reactivated adenovirus infection 5.5 months later and died, despite resumption of treatment with ribavirin combined with vidarabine. Two of 3 surviving patients received bone marrow from a matched sibling. Only 1 of 9 patients with definite or probable disease showed a clinical response to ribavirin therapy. We are uncertain whether the clearance of adenovirus was circumstantial. Indeed, 11 of 13 untreated patients spontaneously recovered. However, most of them received non-T cell-depleted bone marrow from matched siblings, had adenovirus isolated at a single site, and had no evidence of adenovirus disease. The most commonly reported adverse effect of ribavirin is reversible mild anemia induced by hemolysis. Such complications were not significant in our series.
Vidarabine is active in vitro against double-stranded DNA viruses, including human adenovirus. It has been reported to be effective in a few cases after HSCT, but only against hemorrhagic cystitis [10, 11] . Our results are appreciably different; indeed, our 7 treated patients showed no benefit from vidarabine, although only 1 had hemorrhagic cystitis.
Cidofovir is a nucleotide analogue of cytosine with potent in vitro activity against herpesviruses, polyomaviruses, and different serotypes of adenoviruses [24] . It recently has been shown to be a therapeutic option in life-threatening disseminated adenovirus diseases [13, 25, 26] . Indeed, of the 16 reported patients who received treatment, 9 (56%) responded. Five (71%) of our 7 treated patients had clearance of adenovirus; however, in 1 of them, infection promptly reactivated. These data should be interpreted with caution, because patients either received cidofovir combined with other treatments or had asymptomatic infections. These encouraging results were obtained at the expense of severe nephrotoxicity, as recently reported in ∼15% of patients [27] . The close temporal relationship between the onset of renal failure, cidofovir administration, and the transient and partially reversible deterioration in renal function that occurred after each course strongly support the role of cidofovir in our observation.
Adenovirus-specific cellular immune responses, particularly long-lived adenovirus-specific CD4 ϩ T cells, have a major role in the prevention and control of viral infections [28] . Downregulation of the host immune response to adenovirus-infected cells facilitates the establishment of persistent and latent infections. Successful treatment of life-threatening adenovirus disease after HSCT with unmanipulated DLI was reported in 3 of 4 cases [1, 14, 17, 29] . The patients were given to 6 1 ϫ 10 CD3 ϩ cells/kg, with no evidence of GVHD, apla-7 1.9 ϫ 10 sia, or interstitial pneumonia. Similarly, DLI (dose range, 1-CD3 ϩ cells/kg, derived from matched unrelated do- 5 10 ϫ 10 nors) produced rapid clearance of virus in 2 of our 3 patients but at the expense of 1 case of fatal idiopathic respiratory failure. Indeed, although unmanipulated polyspecific donor T cells as treatment of Epstein-Barr virus-associated lymphoproliferative disorders are effective therapy, such treatments occasionally are complicated by GVHD and idiopathic interstitial pneumonia [30] . To circumvent these problems, several groups are exploring the use of viral antigen-specific cytotoxic T cells, which not only reconstitute host cellular immunity to Epstein-Barr virus or CMV, but also establish populations of cytotoxic T lymphocyte precursors that survive for a prolonged period and may respond to viral challenge [31, 32] . The other approach to reduce the risk of GVHD is to transduce T cells with a suicide gene, as evaluated by Bonini and colleagues [33] . Preclinical studies are underway to establish systems for generating adenovirus-specific cytotoxic T lymphocytes by using donor peripheral blood dendritic cells as antigen-presenting cells [34] . The extensive cross-reactivity of adenovirus-specific cytotoxic T cells suggests that adoptive transfer of cytotoxic T lymphocytes generated in vitro against a particular serotype could protect bone marrow recipients from infections of all serotypes [35] .
In conclusion, ribavirin, vidarabine, and high-dose IVIGs are ineffective for patients who are at high risk for disseminated adenovirus disease. Conversely, cidofovir or adoptive immunotherapy seem to be encouraging approaches. Invasive adenovirus disease is associated with a very high risk of mortality. Therefore, it is imperative to treat adenovirus infection in a manner similar to that used for CMV infection, before it develops into disease. Two different approaches could be considered. In the first, preemptive therapy, patients are given cidofovir and/or DLI or adoptive transfer of specific cytotoxic T lymphocytes when adenovirus infections are first identified. In the second, prophylactic, approach, similar treatments are given to all patients who are at high risk of disseminated infection. Given the potential risk of such approaches, we have to better define this high-risk subgroup of patients. Patients undergoing allogeneic transplantation complicated by moderate to severe acute GVHD with у2 sites of infection are at the greatest risk of developing disseminated adenovirus disease. Among allogeneic recipients, there was a higher incidence of adenovirus disease in patients with unrelated or HLA-mismatched grafts than in patients with related HLA-matched grafts. In our series, a pediatric population, unrelated or mismatched related bone marrow, T cell-depleted BMTs, and prophylactic or curative antithymocyte globulins were significant high-risk factors (data not shown).
To accomplish this, we need more rapid and sensitive diagnostic approaches. Indeed, it takes several days or weeks to isolate adenoviruses from clinical specimens with culture-based diagnosis, whereas PCR analysis or in situ hybridization results are available within 24 h of testing [36, 37] . Further studies are needed to evaluate the sensitivity and clinical value of these techniques.
No significant factor is a definite indicator of which patients will respond to ribavirin therapy and which patients will not [1] . However, there is a trend toward better responses to ribavirin or vidarabine therapy among patients with isolated adenovirus-associated hemorrhagic cystitis, particularly for some recipients who receive transplants from a genetically close donor [23] . Moreover, Howard et al. [1] recently postulated that early preemptive therapy with ribavirin could prevent the development of adenovirus dissemination in high-risk patients. We agree with this strategy but not with the choice of the drug, which was ineffective in our experience.
In our study, 2 factors correlated significantly with an increased risk of treatment failure: acute GVHD grade у3 and a long delay between first isolation of adenovirus and treatment. In conclusion, prospective trials are needed to determinate the efficacy of these different approaches for prevention and treatment of serious adenovirus disease in the context of hematopoietic stem cell transplantation.
